Atlentis Therapeutics is developing breakthrough treatments for fibrotic disease and associated cancer. In its lead program, Alentis is exploiting a previously undiscovered functional role of Claudin-1 (CLDN1) and its associated pathways in disease biology to develop breakthrough therapies for fibrotic diseases and associated cancers.
These include chronic liver and kidney disease as well as hepatobiliary cancer.
Moreover, Alentis builds on a unique cell-based platform modeling the clinical cell circuits of advanced liver disease. Using this cutting-edge platform based on clinically relevant read-outs combined with single cell RNASeq of patient liver tissues, Alentis is developing new medicines for treatment of fibrosis and advanced liver disease – a key unmet medical need rising on a global level.